Literature DB >> 10329541

Activation of the interferon-inducible (2'-5') oligoadenylate synthetase by the Epstein-Barr virus RNA, EBER-1.

T V Sharp1, D A Raine, D R Gewert, B Joshi, R Jagus, M J Clemens.   

Abstract

The 2'-5' oligoadenylate synthetases and the protein kinase PKR are both interferon-induced, double-stranded RNA-dependent proteins that play important roles in the antiviral effects of the interferons and in cellular growth control. Both enzymes are activated by natural or synthetic dsRNAs and by single-stranded RNAs that possess extensive secondary structure. This report describes the effects of the small Epstein-Barr virus-encoded RNA EBER-1 on the regulation of 2-5(A) synthetase activity. We demonstrate that EBER-1 RNA binds to and activates the human 40-kDa 2-5(A) synthetase in a dose-dependent manner. The efficiency of EBER-1 as an activator of 2-5(A) synthetase is approximately 25% of that of the synthetic double-stranded RNA poly(I)/poly(C), and poly(I)/poly(C) further stimulates enzyme activity even in the presence of a high concentration of EBER-1. Conversely, EBER-1 neither stimulates nor inhibits 2-5(A) synthetase that has been activated by a high concentration of poly(I)/poly(C). Competitive binding assays suggest that the relative affinity of the enzyme for poly(I)/poly(C) is considerably higher than that for EBER-1. Our data indicate that EBER-1, like VAI RNA of adenovirus, TAR RNA of HIV-1, and Rex-RE RNA of HTLV-1, is able to activate the 2-5(A) synthetases. The significance of why several viruses may activate the 2-5(A) synthetase/RNase L-mediated RNA degradation pathway is discussed. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329541     DOI: 10.1006/viro.1999.9689

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Transfection of single-stranded hepatitis A virus RNA activates MHC class I pathway.

Authors:  K Suzuki; M Yanagi; A Mori-Aoki; E Moriyama; K J Ishii; L D Kohn
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

2.  Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis.

Authors:  I K Ruf; P W Rhyne; C Yang; J L Cleveland; J T Sample
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  The Flvr-encoded murine oligoadenylate synthetase 1b (Oas1b) suppresses 2-5A synthesis in intact cells.

Authors:  H Elbahesh; B K Jha; R H Silverman; S V Scherbik; M A Brinton
Journal:  Virology       Date:  2010-11-05       Impact factor: 3.616

Review 4.  Diverse functions of RNase L and implications in pathology.

Authors:  Catherine Bisbal; Robert H Silverman
Journal:  Biochimie       Date:  2007-02-20       Impact factor: 4.079

5.  Cloning of the rhesus lymphocryptovirus viral capsid antigen and Epstein-Barr virus-encoded small RNA homologues and use in diagnosis of acute and persistent infections.

Authors:  P Rao; H Jiang; F Wang
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA.

Authors:  Jian-Qiu Han; David J Barton
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

Review 7.  RNA regulation of the antiviral protein 2'-5'-oligoadenylate synthetase.

Authors:  Samantha L Schwartz; Graeme L Conn
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-04-15       Impact factor: 9.957

Review 8.  Epstein-Barr virus latency: current and future perspectives.

Authors:  Bettina Kempkes; Erle S Robertson
Journal:  Curr Opin Virol       Date:  2015-10       Impact factor: 7.090

Review 9.  Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines.

Authors:  Jesper Melchjorsen
Journal:  Viruses       Date:  2013-01-31       Impact factor: 5.048

10.  Activation of the interferon-inducible 2'-5'-oligoadenylate synthetase gene by hepatitis C virus core protein.

Authors:  A Naganuma; A Nozaki; T Tanaka; K Sugiyama; H Takagi; M Mori; K Shimotohno; N Kato
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.